NEWTON, Mass.--(BUSINESS WIRE)--July 25, 2006--Pro-Pharmaceuticals (Amex: PRW - News), a developer of novel nanotechnology carbohydrate compounds, today announced it has filed a clinical protocol with the U.S. Food & Drug Administration (FDA) for an open-label, up to 50 patient, multi-center Phase II study of DAVANAT® with Avastin®, 5-Fluorouracil (5-FU) and leucovorin as a first line treatment for locally advanced and unresectable or metastatic colorectal cancer in patients unable to tolerate intensive chemotherapy.
